Joseph Eron
@joseph_eron
ID: 2980545639
16-01-2015 02:09:35
281 Tweet
579 Followers
63 Following
Have to agree with Jose R Arribas though more data to come with DTG/DRVboosted. Two very high barrier agents. LEN and CAB both are not in that category. CROI will be great this year-go if you can
Potentially the next step in the evolution of #HIV treatment: Gilead Sciences' lenacapavir (Sunlenca) + 2 broadly neutralizing antibodies (teropavimab & zinlirvimab) maintained viral suppression for 6 months, Joseph Eron of UNC-Chapel Hill reported at #CROI2023 poz.com/article/sunlen…
National guidelines may have played a role in #equitable access to new therapy. #racial #disparities #HIV #ART Check out Lauren Zalla’s work guided by Ada Adimora and Joseph Eron... The❓now is how ➡️unc.live/3JjgFvr
Join Joseph Eron and Princy N. Kumar, MD on 4/11 in DC for 'CROI 2023 Update: What Did We Learn?'. Earn 2.50 AMA, ANCC, and ACPE credits. Dinner provided by CCO. Register for free: bit.ly/3LZMjQt
Looking forward to the launch of this innovative training program UNC Division of Infectious Diseases . Applicants for combined ID/EIS training need to apply separately to EIS and ID programs. Apply now for EIS. Application period open through June 5, 2023. Joe Tucker, MD David van Duin David Alain Wohl
Large NIH study, Led by Steve Grinspoon and Pam Douglas, in partnership with ACTG, demonstrates that statin therapy in low and mod CVD-risk people with HIV decreases CVD outcomes. ACTG Network niaid.nih.gov/news-events/da…
Thrilled to be a part of this ACTG Network #COVID19 UW Positive Research Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19 | Annals of Internal Medicine acpjournals.org/doi/10.7326/M2…
Terrific! Congratulations to the authors including David van Duin UNC Division of Infectious Diseases Institute for Global Health & Infectious Diseases